ATHA Athira Pharma

Athira Pharma to Participate in Upcoming June Conferences

Athira Pharma to Participate in Upcoming June Conferences

BOTHELL, Wash., May 31, 2023 (GLOBE NEWSWIRE) --  (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences:

Jefferies Healthcare Conference

Fireside Chat on Wednesday, June 7, 2023, at 8:30 a.m. ET in New York

Goldman Sachs 44th Annual Global Healthcare Conference

Presentation on Wednesday, June 14, 2023, at 8:40 a.m.PT in Dana Point, California

Live webcasts of the Jefferies fireside chat and Goldman Sachs presentation can be accessed from the Investors section of the Athira website at . An archived replay of the webcasts will be available for at least 30 days following the event.

About Athira Pharma, Inc.

Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action. Athira is currently advancing its pipeline of therapeutic candidates targeting the HGF/MET neurotrophic system for Alzheimer’s and Parkinson’s disease, Dementia with Lewy bodies and amyotrophic lateral sclerosis (ALS). For more information, visit . You can also follow Athira on , , and @athirapharma on .

Investor & Media Contact:

Julie Rathbun

Athira Pharma



206-769-9219



EN
31/05/2023

Underlying

ATHAAthira Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Athira Pharma

 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Deve...

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors and TCGX Supports Development of Lasofoxifene through Phase 3 Clinical Topline Data Readout and Regulatory Milestones Conference Call Today at 8:30 am Eastern Time BOTHELL, Wash., De...

December 18, 2025 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Reports Third Quarter 2025 Financial Results and Provide...

Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update Continuing to explore strategic alternatives focusing on maximizing stockholder value   Presented results from Phase 1 clinical trial of ATH-1105 in healthy volunteers demonstrating a favorable safety and tolerability profile as well as dose proportional pharmacokinetics and CNS penetration, supporting continued clinical development  BOTHELL, Wash., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to...

November 6, 2025 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Announces Reverse Stock Split

Athira Pharma Announces Reverse Stock Split BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will effect a 10-for-1 reverse stock split of Athira’s issued and authorized common stock. Athira’s stockholders previously approved the reverse stock split and granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse st...

September 11, 2025 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 202...

Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented results from its Phase 1 clinical trial of ATH-1105 in healthy volunteers at the ALS Nexus 2025 conference in Dallas, Texas. ALS Nexus convenes leading experts from the ALS community, including researchers, healthcare professionals, advocates and individuals living with amyotrophic lateral ...

August 14, 2025 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Reports Second Quarter 2025 Financial Results and Provid...

Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development BOTHELL, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended June 30, 2025,...

August 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch